Publication: Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients
Issued Date
2010-06-01
Resource Type
ISSN
09575235
Other identifier(s)
2-s2.0-77951883174
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Coagulation and Fibrinolysis. Vol.21, No.4 (2010), 354-362
Suggested Citation
Ampaiwan Chuansumrit, Sumate Teeraratkul, Suthep Wanichkul, Suporn Treepongkaruna, Nongnuch Sirachainan, Samart Pakakasama, Pracha Nuntnarumit, Suradej Hongeng Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients. Blood Coagulation and Fibrinolysis. Vol.21, No.4 (2010), 354-362. doi:10.1097/MBC.0b013e3283389500 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/29632
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients
Other Contributor(s)
Abstract
A total of 108 episodes among 103 nonhemophilic pediatric patients (nine newborns, 16 infants and 78 children) treated with recombinant factor-activated VII (rFVIIa) were evaluated retrospectively. These episodes were divided into two groups: group 1 included 86 occurrences for hemorrhagic control of ongoing massive bleeding due to thrombocytopenia and coagulopathy unresponsive to blood component therapy in patients with dengue hemorrhagic fever, life-threatening, intraoperative and postoperative bleeding; group 2 included 22 episodes for prevention of hemorrhage with invasive procedures in patients with chronic liver disease and associated coagulopathy, and patients without preexisting hemostatic disorder but at high risk due to their underlying diagnosis and required surgical intervention. The effective control of hemostasis response rate in group 1 was significantly lower than in group 2. The median total dose per kilogram of rFVIIa group 1 was twice that of group 2. The overall case-fatality rate related to bleeding or underlying conditions was 31.1% (32/103). Adverse events were observed in three patients (2.9%) receiving rFVIIa for control of intraoperative and postoperative bleeding in the setting of corrective cardiac surgery. These results support the safety and potential benefit of rFVIIa for control and prevention of hemorrhage in pediatric patients without congenital hemophilia. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.